세계 녹내장 배액 기기 시장 규모는 2023년 6억 4,057만 달러, 2030년에는 11억 8,439만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 연평균 11.95% 성장할 것으로 예상됩니다. 녹내장 배액 기기 수요 증가는 주로 전 세계적으로 녹내장 유병률 증가, 당뇨병 및 고혈압과 같은 생활습관병 증가, 노인 인구의 부담 증가, 제품 개발의 기술 혁신 등이 녹내장 배액 기기 시장을 견인할 것으로 예상됩니다.
녹내장 배액 기기 시장 역학
녹내장 배액 기기에 대한 수요 증가의 주요 요인은 전 세계적으로 녹내장 유병률이 증가하고 있기 때문입니다. 예를 들어, 2022년 Delhi Ophthalmological Society가 제공 한 데이터에 따르면 녹내장은 전 세계적으로 돌이킬 수없는 실명의 주요 원인입니다. 같은 자료에 따르면 2020년 전 세계 녹내장 환자 수는 7,960만 명으로 추산됩니다. 또한 앞서 언급한 자료에 따르면 인도는 녹내장 환자가 두 번째로 많은 지역이 될 것으로 예상되며, 인도의 녹내장 환자 유병률은 2020년에 1,190만 명에 달할 것으로 추정됩니다. 따라서 녹내장 유병률 증가는 예측 기간(2024-2030) 동안 녹내장 장치 시장을 밀어 붙일 수 있습니다.
또한, 녹내장 배액 기기 시장의 성장을 이끄는 또 다른 주요 요인은 당뇨병과 고혈압의 유병률 증가가 될 수 있습니다. 예를 들어, 2023년에 발표된 세계보건기구(WHO) 데이터에 따르면 2020년 전 세계적으로 약 4억 2,200만 명이 당뇨병을 앓고 있으며, 매년 약 150만 명이 당뇨병을 앓고 있습니다. 이처럼 당뇨병은 녹내장 발병 가능성을 두 배로 증가시키고, 조기에 치료하지 않으면 시력 저하 및 실명으로 이어질 수 있기 때문에 예측 기간(2024-2030년) 동안 녹내장 기기 시장 수요를 증가시킬 수 있습니다.
또한 2020년 Pan American Health Organization이 발표한 최신 데이터에 따르면 전 세계 성인 인구의 30% 이상이 고혈압을 앓고 있으며, 전 세계적으로 10억 명 이상이 고혈압을 앓고 있다고 합니다. 또한 세계보건기구가 2023년에 발표한 데이터에 따르면 2020년 중국에서는 약 2억 7,000만 명이 고혈압을 앓고 있다고 합니다. 또한 고혈압은 눈의 동맥을 손상시켜 안압 상승에 따른 혈류 변화에 적응하지 못하게 만들어 녹내장의 위험 요인으로 간주됩니다.
앞으로 위의 요인들은 예측 기간 동안 세계 녹내장 배액 기기 시장의 성장에 기여할 것입니다.
그러나 장치와 관련된 합병증과 녹내장 배액장치의 제한된 기간 동안의 효과로 인해 녹내장 배액장치 시장 성장에 어려움을 겪을 것으로 예상됩니다.
또한, 코로나19 팬데믹 기간 동안 전 세계적으로 녹내장 수술 건수와 기업 수익 부문이 크게 감소하여 녹내장 배액 기기 시장의 성장이 단기간에 제한되었습니다. 그러나 2020년 하반기에 Glaukos Corporation의 차세대 녹내장 배액 기기 iStent inject W를 비롯한 여러 제품이 출시될 예정이기 때문에 녹내장 배액 기기 시장은 팬데믹 이후 시나리오에서 전 세계적으로 회복세를 보일 것으로 예상됩니다. 또한, 녹내장 배액 기기 시장은 보다 명확한 예방적 접근 방식 및 가이드라인과 함께 봉쇄 규제 완화 및 선택적 수술 재개로 인해 다시 성장할 수 있습니다. 또한 2020년 하반기에 전 세계적으로 수많은 코로나19 백신이 승인되고 투여되면서 의료 서비스를 포함한 다양한 분야의 활동이 크게 회복되어 녹내장 배액 기기 시장의 건전한 회복기에 접어들 수 있는 길을 열었습니다.
녹내장 배액 기기 시장 부문 분석
녹내장 배액 기기 시장의 제품 부문에서는 저침습적 녹내장 수술 장치(MIGS) 카테고리가 2030년까지 6억 8,146만 달러에 달할 것으로 예상되며, 2024-2030년의 예측 기간 동안 11.95%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.
이 보고서는 세계 녹내장 배수장치 시장에 대해 조사 분석했으며, 시장 규모와 예측, 촉진요인 및 과제, 기업 및 제품 프로파일 등의 정보를 전해드립니다.
Glaucoma Drainage Devices Market By Product Type (Conventional Glaucoma Drainage Devices [Valveless Glaucoma Drainage Devices And Valved Glaucoma Drainage Devices], Minimally Invasive Glaucoma Surgery (Migs) Devices [Schlemm's Canal Migs Devices, Suprachoroidal Migs Devices, And Subconjunctival Migs Devices]), By End-User (Hospitals, Ambulatory Surgical Centers, And Specialty Clinics), by geography, is anticipated to grow at a significant CAGR forecast till 2030 due to rising prevalence of glaucoma and increasing prevalence of diabetes & hypertension
The global glaucoma drainage devices market was valued at USD 640.57 million in 2023, growing at a CAGR of 11.95% during the forecast period from 2024 to 2030, to reach USD 1,184.39 million by 2030. The increase in demand for glaucoma drainage devices is primarily due to the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development are expected to boost the market for glaucoma drainage devices.
Glaucoma Drainage Devices Market Dynamics:
The key factor responsible for the increasing demand for glaucoma drainage devices is the rising prevalence of glaucoma conditions worldwide. For instance, as per the data provided by the Delhi Ophthalmological Society in 2022, glaucoma is the leading cause of irreversible blindness across the world. As per the same source, in 2020, the global burden of glaucoma was estimated to be 79.6 million. Also, according to the aforementioned source, India is expected to be the second-largest home of glaucoma patients, and the estimated prevalence of glaucoma cases in India was estimated to be 11.9 million in 2020. Therefore, the increasing prevalence of glaucoma could boost the glaucoma devices market during the forecast period (2024-2030).
Further, another key factor that is responsible for the growth of the glaucoma drainage devices market could be the increasing prevalence of diabetes & hypertension. For instance, as per the World Health Organization data published in the year 2023, in 2020, about 422 million people worldwide had diabetes, and about 1.5 million people suffer from diabetes every year. Thus, diabetes doubles the chances of having glaucoma, which can lead to vision loss and blindness if not treated early, which can increase the glaucoma devices market demand during the forecast period (2024-2030).
Furthermore, according to the latest data published by Pan American Health Organization in 2020, hypertension had affected more than 30% of the adult population worldwide, accounting for more than one billion people around the world. Also, as per the data published by World Health Organization in the year 2023, in 2020, about 270 million people were affected by hypertension in China. Moreover, the blood arteries in the eyes may be damaged by hypertension and unable to adjust to changes in blood flow as a result of rising ocular pressure, which is considered to be a risk factor for glaucoma.
Henceforth, the above-mentioned factors will contribute to the global glaucoma drainage devices market growth during the forecasted period.
However, complications associated with the devices and efficacy of glaucoma drainage devices for a limited timeframe are expected to pose a challenge to the glaucoma drainage devices market growth.
Additionally, there was a significant reduction in the glaucoma surgical volume procedures and company revenue segments across the globe during the COVID-19 pandemic, which restricted the glaucoma-drainage device market growth for a brief period. However, due to the launch of several products such as the iStent inject W by Glaukos Corporation, a next-generation glaucoma drainage device, in the second half of 2020, the glaucoma drainage devices market potentially redeem itself across the globe in the post-pandemic scenario. Also, the easing of lockdown restrictions and resumed elective surgeries along with more clear precautionary approaches and guidelines lead to the renewed market growth of glaucoma drainage devices. Moreover, owing to the approval and administration of numerous COVID-19 vaccines across the globe in the second half of 2020, there was a significant improvement in the resumption of activities across various domains, including healthcare services, thereby paving the way for a sound period of recovery for the glaucoma drainage devices market.
Glaucoma Drainage Devices Market Segment Analysis:
Glaucoma Drainage Devices Market By Product Type (Conventional Glaucoma Drainage Devices [Valveless Glaucoma Drainage Devices and Valved Glaucoma Drainage Devices], Minimally Invasive Glaucoma Surgery (MIGS) Devices [Schlemm's Canal MIGS Devices, Suprachoroidal MIGS Devices, and Subconjunctival MIGS Devices]), End-User (Hospitals, Ambulatory Surgical Centers, and Specialty Clinics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the product segment of the glaucoma drainage devices market, the Minimally Invasive Glaucoma Surgery devices (MIGS) category is expected to dominate the market and is estimated to grow at a CAGR of 11.95% during the forecast period from 2024-2030 to reach USD 681.46 million by 2030. The MIGS devices are categorized into Schlemm's Canal MIGS Devices, Suprachoroidal MIGS Devices, and Subconjunctival MIGS Devices. Schlemm's canal MIGS devices are used to increase trabecular outflow by bypassing the trabecular meshwork and directing aqueous humor into Schlemm's canal. Since the trabecular meshwork is considered the primary site of resistance to aqueous humor outflow, bypassing this structure and directing aqueous flow from the anterior chamber directly into Schlemm's canal seemed to be a reasonable approach that increases the demand for these devices.
Moreover, as per the various studies, the Intraocular Pressure (IOP)-lowering efficacy of subconjunctival MIGS appears to approach that of traditional filtering surgery, thereby offering the possibility that they might have utility in more advanced or normal-pressure glaucoma. Further, recently, in May 2022, PRESSERFLO, subconjunctival MIGS devices, was approved by Health Canada to reduce in patients with primary open-angle glaucoma (POAG) whose IOP is not controlled when using maximum tolerated glaucoma medications
Hence, all the aforementioned factors will lead to the segmental growth of the glaucoma drainage devices market in the coming years.
North America is expected to dominate the overall Glaucoma Drainage Devices Market:
Among all the regions, North America dominated the market in the year 2023 and is estimated to grow at a CAGR of 11.06% during the forecast period from 2024 to 2030 to reach USD 453.39 million by 2030. This domination can be primarily attributed to the rising cases of lifestyle-related disorders such as diabetes and the rising geriatric population.
For instance, as per the National Diabetics Statistics Report published by the Centers for Disease Control and Prevention (CDC) in the year 2020, about 34.2 million Americans had diabetes 2020. The report further stated that approximately 88 million Americans showed pre-diabetes levels. The CDC considers diabetes to be one of the major risk factors that may lead to glaucoma development. Thus, diabetes doubles the chances of having glaucoma, which can lead to vision loss and blindness if not treated early, which can increase the glaucoma devices market demand during the forecast period (2024-2030).
According to the data published by the World Bank Group in the year 2023, approximately 9,822,231 population in Mexico were aged 65 years and above in 2020. Thus, the geriatric population is more susceptible to developing glaucoma is also expected to raise the demand for glaucoma drainage devices in the upcoming years.
The market presence of key manufacturers such as Johnson & Johnson, Allergan, and others active in manufacturing glaucoma drainage devices will also contribute to the market growth of these devices.
Thus, all the above-mentioned factors are projected to surge the market for glaucoma drainage devices in the region.
Glaucoma Drainage Devices Market Key Players:
Some of the key market players operating in the glaucoma drainage devices market include Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation, Santen Pharmaceutical Co., Ltd, NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and others.
Recent Developmental Activities in the Glaucoma Drainage Devices Market:
In October 2022, Alcon, the world leader in eye care committed to enabling people to see brilliantly, announced the completion of its previously announced acquisition of Ivantis®, maker of the ground-breaking Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) tool intended to reduce eye pressure for open-angle glaucoma patients in conjunction with cataract surgery.
In November 2022, iSTAR Medical a MedTech company committed to delivering breakthrough eye care solutions through minimally-invasive implants designed for bio-integration, received European market approval for glaucoma implant MINIject designed to significantly reduce IOP by enhancing aqueous humor outflow from the anterior chamber to the suprachoroidal space.
In May 2022, Santen Canada Inc., a subsidiary of Santen Pharmaceutical Co., a global company focused on developing ophthalmology products, received Health Canada approval for PRESERFLOTM MicroShunt. This surgical device helps drain eye fluid and reduce intraocular pressure (IOP) in patients with POAG.
Key Takeaways from the Glaucoma Drainage Devices Market Report Study:
Target Audience who can be benefited from the Glaucoma Drainage Devices Market Report Study
Frequently Asked Questions for the Glaucoma Drainage Devices Market:
Glaucoma drainage devices have been designed to divert the aqueous humor from the anterior chamber to the external reservoir. A fibrous capsule is formed in about 4-6 weeks after the surgery and regulates the flow. The devices are extensively used in complicated glaucoma, comprising uveitic glaucoma, neovascular glaucoma, and pediatric and developmental glaucoma.
The global glaucoma drainage devices market was valued at USD 640.57 million in 2023, growing at a CAGR of 11.95% during the forecast period from 2024 to 2030, to reach USD 1,184.39 million by 2030.
The major factors driving the demand for glaucoma drainage devices are the rising prevalence of glaucoma across the globe, increasing lifestyle disorders such as diabetes & hypertension, the growing burden of the old age population, and technical innovation in product development.
Some of the key market players operating in the glaucoma drainage devices market include Johnson & Johnson, AbbVie Inc, Alcon Inc, Glaukos Corporation, Santen Pharmaceutical Co., Ltd, NovaEye Medical Limited, iSTAR Medical SA, Rheon Medical SA, Advanced Ophthalmic Innovations Pte Ltd, New World Medical Inc, Aurolab, and others.
Among all the regions, North America is expected to occupy a major share in the overall glaucoma drainage devices market during the forecasted years, 2024-2030. This domination can be primarily attributed to the rising cases of lifestyle-related disorders such as diabetes and the rising geriatric population.